Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash from Investing Activities (2024 - 2025)

Silence Therapeutics' Cash from Investing Activities history spans 2 years, with the latest figure at -$53.3 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 180.66% year-over-year to -$53.3 million; the TTM value through Dec 2025 reached -$48.0 million, down 118.48%, while the annual FY2025 figure was -$48.0 million, 118.48% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$53.3 million at Silence Therapeutics, down from $51.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $66.1 million in Q4 2024 and bottomed at -$53.3 million in Q4 2025.